Blar i Publikasjoner fra Cristin - Sykehuset Innlandet HF på emneord "biosimilar; chronic inflammatory disease; drug costs; health economics; infliximab; switching"
Viser treff 1-1 av 1
-
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial
(Journal article; Peer reviewed, 2019)BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not ...